Last edition
News about "Acute Myeloid Leukemia (AML)"
Platform Technologies Drive USD 211 Billion Surge in Precision Cancer Treatment
The rapid rise of platform technologies has added USD 211 billion in value to the precision oncology landscape, with immunotherapies now accounting for more than 45 percent of global anticancer drug revenues—underscoring strong investor confidence in biologically targeted treatment approaches.
Acute Myeloid Leukemia (AML) | 12/12/2025 | By Akanki
Moleculin Launches Grant-Funded Study of Annamycin for Pancreatic Cancer at UNC-Chapel Hill
Moleculin has initiated a grant-funded preclinical programme at the University of North Carolina at Chapel Hill to evaluate Annamycin in pancreatic cancer, including its use alongside novel therapeutic agents and modalities. Early studies suggest Annamycin may effectively target key drivers of the disease.
Acute Myeloid Leukemia (AML) | 15/11/2025 | By Dineshwori | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy